目的 探討復(fù)方銀杏通脈口服液聯(lián)合厄貝沙坦治療高血壓的臨床療效。方法 選取2017年5月-2017年11月在深圳市龍華區(qū)中心醫(yī)院進(jìn)行診治的106例高血壓患者，隨機(jī)分為對(duì)照組和治療組，每組各53例。對(duì)照組口服厄貝沙坦片，起始劑量為0.15 g/次，根據(jù)病情可增至0.3 g/次，1次/d；治療組在對(duì)照組治療基礎(chǔ)上口服復(fù)方銀杏通脈口服液，10 mL/次，3次/d。兩組患者均連續(xù)治療4周。觀察兩組的臨床療效，比較兩組治療前后24 h平均收縮壓（mSBP）、24 h平均舒張壓（mDBP）、臨床癥狀積分、單核細(xì)胞趨化蛋白-1（MCP-1）、可溶性凝集素樣氧化型低密度脂蛋白受體-1（sLOX-1）、基質(zhì)金屬蛋白酶-9（MMP-9）、內(nèi)皮素（ET）、一氧化氮（NO）的變化情況。結(jié)果 治療后，對(duì)照組和治療組的總有效率分別為81.13%、98.11%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組24 h mSBP、24 h mDBP、頭痛積分、耳鳴積分、頭暈積分均較治療前顯著降低，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；治療后，治療組24 h mSBP、24 h mDBP、頭痛積分、耳鳴積分、頭暈積分水平顯著低于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組血清MCP-1、sLOX-1、MMP-9、ET-1水平均顯著降低，但NO水平顯著增高，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；治療后，治療組MCP-1、sLOX-1、MMP-9、ET-1水平低于對(duì)照組，NO水平高于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 復(fù)方銀杏通脈口服液聯(lián)合厄貝沙坦治療高血壓具有較好的臨床療效，可有效降低患者血壓，改善臨床癥狀，還可改善血清因子水平，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To explore the clinical efficacy of Compound Yinxing Tongmai Oral Liquid combined with irbesartan in treatment of hypertension. Methods Patients (106 cases) with hypertension in Shenzhen Longhua District Central Hospital from May 2017 to November 2017 were randomly divided into control (53 cases) and treatment (53 cases) groups. Patients in the control group were po administered with Irbesartan Tablets, and the initial dosage was 0.15 g/time, which could be increased to 0.3 g/time, once daily. Patients in the treatment group were po administered with Compound Yinxing Tongmai Oral Liquid on the basis of the control group, 10 mL/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and the changes of 24 h mSBP, 24 h mDBP, clinical symptom integral, MCP-1, sLOX-1, MMP-9, ET, and NO in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 81.13% and 98.11%, respectively, and there was difference between two groups (P < 0.05). After treatment, 24 h mSBP, 24 h mDBP, headache integral, tinnitus integral, and dizziness integral in the two groups were significantly reduced, and the difference was statistically significant in the same group (P < 0.05). After treatment, 24 h mSBP, 24 h mDBP, headache integral, tinnitus integral, and dizziness integral in the treatment group were lower than those in the control group, and there was difference between two groups (P < 0.05). After treatment, MCP-1, sLOX-1, MMP-9, and ET-1 in two groups were significantly reduced, but NO was significantly increased, and the difference was statistically significant in the same group (P < 0.05). After treatment, MCP-1, sLOX-1, MMP-9, and ET-1 in the treatment group were lower than those in the control group, but NO was significantly higher than that in the control group, and there was difference between two groups (P < 0.05). Conclusion Compound Yinxing Tongmai Oral Liquid combined with irbesartan has remarkable clinical effect in treatment of hypertension, and can effectively reduce the blood pressure, and can improve the clinical symptoms and serum factor levels, which has a certain clinical application value.